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Abstract
Background: Nivolumab (Opdivo™) is a novel IgG4 subclass programmed death-1 (PD-1) inhibiting antibody that
has demonstrated breakthrough-designation anti-tumor activity. To date, clinical trials of nivolumab and other
checkpoint inhibitors have generally excluded patients with solid organ transplantation and patients with
concurrent immunosuppression. However, organ transplant recipients are at high-risk of development of
malignancy as a result of suppressed immune surveillance of cancer.
Case presentation: We illustrate the outcomes of a 63 year-old type I diabetic female patient who developed
pulmonary metastatic, BRAF wild-type cutaneous melanoma 10 years after renal transplantation. After downward
titration of the patient’s immunosuppressive medications and extensive multidisciplinary review, she was treated
with nivolumab in the first-line setting. Within 1 week of administration, the patient experienced acute renal
allograft rejection, renal failure and concurrent diabetic ketoacidosis due to steroid therapy. Allograft function did
not return, but patient made a full clinical recovery after being placed on hemodialysis. Subsequently, the patient
had clinical disease progression off therapy and required re-challenge with nivolumab on hemodialysis, resulting in
ongoing clinical and radiographic response.
Conclusions: This case illustrates multiple practical challenges and dangers of administering anti-PD1 immune
checkpoint inhibitors to patients with solid-organ transplantation including need for titration of immunosuppressive
medications, risks of allograft rejection, and treatment during hemodialysis.
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Background
Novel cancer immunotherapies targeting programmed-
death-1 (PD-1) and its ligand (PD-L1) have demonstrated
remarkable anti-cancer activity and survival benefit lead-
ing to regulatory approvals in metastatic melanoma, non-
small cell lung cancer, and renal cell carcinoma [1, 2].
Clinical trials of nivolumab (Opdivo™), an IgG4 subclass
PD-1-inhibiting antibody, and other similar immune
checkpoint inhibitors have generally excluded patients
with solid organ transplantation and patients with concur-
rent immunosuppression. However, organ transplant re-
cipients are a high-risk cohort for developing metastatic
cancer as a result of suppressed immune surveillance [3].
Immune checkpoint inhibition with anti-cytotoxic T-
lymphocyte-associated protein-4 (CTLA-4) antibodies
have previously been reported as successfully and safely
administered with low dose-immunosuppression in
liver transplant [4, 5] and renal transplant patients [6].
Recent literature has seen an emerging trend of anti-
PD-1 medications being linked to rejection in trans-
plant patients [7–10]. Herein we report a case of acute
renal allograft rejection seven days after administration
of first dose of nivolumab in the setting of concomitant
radiological response of the metastatic melanoma.
Case presentation
A 63 year-old female with longstanding type-1 diabetes
mellitus and hypertension developed chronic renal fail-
ure in 2002 and underwent a pre-emptive renal allograft
transplant from her donor husband in 2004 without
requiring prior dialysis. Both the donor and recipient
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were cytomegalovirus-negative. She received basiliximab
20 mg prior to her transplant surgery and another
20 mg on day 4 post-transplant. Following transplant-
ation she was immunosuppressed with mycophenolate
mofetil, prednisone and tacrolimus. She had longstand-
ing stable kidney function following transplantation with
a baseline GFR of 84 mL/min and a creatinine of 80
micromol/L. Her past medical history was remarkable
for iatrogenic hypothyroidism following parathyroidec-
tomy for primary hyperparathyroidism, and she had no
prior history of malignancy.
In April 2015, after ten years of immunosupression, she
developed an irregular hyperpigmented and evolving
lesion on her left upper back which was resected in May
2015. The biopsy of the left scapular site revealed a super-
ficial spreading invasive melanoma with a maximum
Breslow thickness of 2.59 mm, Clark level of IV, with,
mitoses of 5/mm2. No ulceration was identified, but
tumor infiltrating lymphocytes and tumor regression were
present. Peripheral margins were uninvolved, but deep
margin was involved by a satellite nodule and microsatelli-
tosis was also present. Wide-local excision and bilateral
axillary lymph node biopsies were performed July 2015, as
lymphoscintigraphy had identified drainage of each of the
lesion to the contralateral axilla when injected with tech-
netium 99 sulfur colloid. Three right axillary lymph nodes
were removed and were negative for malignancy, but 1 left
axillary lymph node was removed and pathology revealed
an 8.5 mm × 7.5 mm melanoma deposit with extranodal
extension. As a result, the patient required a wide local
excision with a 2 cm margin and pathology demonstrated
residual disease and microsatellites, with negative margins.
A second lesion was excised at the time of surgery in the
right scapula, again consistent with superficial spreading
invasive melanoma, Breslow thickness 1 mm, Clark level
II, without ulceration, no mitoses and clear margins
(pT1a). Completion lymph-node dissection August 2015
retrieved 22 lymph nodes, all of which were negative for
melanoma, with final American Joint Committee on
Cancer (AJCC) pathological staging of pT3aN2c.
Staging CT in July 2015 showed a non-specific
6.5 mm non-calcified right lower lobe (RLL) lung nod-
ule, not previously present. BRAF mutation test of the
with real-time PCR assay using the Qiagen BRAF RGQ
kit was BRAF wild-type. The patient was not offered ad-
juvant radiotherapy and declined high-dose adjuvant
interferon.
Follow-up CT imaging in October 2015 demonstrated
increase in size of the RLL lung nodule and the appear-
ance of at least eight new subcentimeter bilateral pulmon-
ary nodules, along with increased mediastinal and left
hilar lymphadenopathy (12 mm). The patient was asymp-
tomatic. A follow-up 2-deoxy-2[F-18] fluoro-D-glucose
(FDG) PET-CT scan in December 2015 demonstrated an
intensely hypermetabolic (SUV max 9.9) left hilar lymph
node enlarging to 16 mm, along with non-FDG avid
pulmonary nodules. An endobronchial ultrasound-guided
biopsy of the hilar lymph node (station 11 L) demon-
strated atypical cells reactive for S100/melanA, confirming
metastatic melanoma. Her case was discussed at the
multidisciplinary tumor board and renal transplantation
team, and a recommendation for anti-PD-1 treatment was
made, based on available safety data and high risk of
cancer-related mortality. Full discussion with patient and
her husband regarding the risks and benefits of treatment
were had and the patient wished to proceed with treat-
ment including unknown risks of allograft rejection.
Immunosuppressive medications were titrated off and she
was left on 10 mg of prednisone daily, with no deterior-
ation in renal function prior to nivolumab administration.
The patient received her first treatment of nivolumab
(anti-PD-1 treatment for metastatic melanoma, single
intravenous dose of 324 mg) on January 7th, 2016. She
reported no subjective toxicities within the first week of
treatment, but on day 8 the patient developed lethargy,
abdominal pain, nausea, vomiting and loose stools (4
times per day), malaise, anorexia and fatigue. Physical
examination demonstrated signs of uremia and concur-
rent tenderness in the lower abdomen at the site of allo-
graft implantation without peritoneal signs. Laboratory
investigations showed a creatinine rise to 577 micromol/L
without any change in electrolytes. The ultrasound Dop-
pler of her kidney showed markedly abnormal appearance
of the transplant kidney with findings suggestive of acute
medical renal disease, poor perfusion and elevated resist-
ive indices concerning for transplant dysfunction. She
received a pulse of corticosteroids (methylprednisolone
500 mg IV × 1), and developed diabetic ketoacidosis
requiring insulin infusion and initiation of hemodialysis.
She had a second pulse of steroids with close endocrino-
logic monitoring and insulin sliding scale, after which
prednisone was tapered down. Renal allograft function did
not return and she was discharged home on hemodialysis.
Nivolumab was withheld and the patient was observed.
Restaging CT thorax on February 2016 demonstrated
a partial resolution of bilateral pulmonary nodules,
hilar lymph nodes and mediastinal lymph nodes but
right lower pleural thickening was noted. However, the
patient had subsequent clinical deterioration 6 weeks
later in March 2016 with dyspnea, cough and hypoxia
with CT thorax showing significant progression of lung
parenchymal disease and multiple new lung nodules.
Infection was ruled out by bronchoscopic examination,
and empiric treatment with piperacillin/tazobactam. After
careful consideration and multidisciplinary review, the
patient was re-administered nivolumab starting April
2016, with both ongoing clinical and radiographic
response. Restaging 12-week CT thorax June 2016 on
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nivolumab shows almost total resolution of previously
noted multiple bilateral pulmonary nodules and consoli-
dations (Fig. 1), but some slight increase in size of medias-
tinal and hilar lymph nodes not meeting criteria for
progression by immune-related response criteria (irRC) in
solid tumors [11]. At the time of publication the patient
has an ongoing (8-month) response in lung metasta-
ses and stable mediastinal/hilar lymph nodes, but slight
growth of a single axillary lymph node.
Conclusions
In this case report, we add to the expanding literature
demonstrating that treatment with an anti-PD-1 antibody
may be associated with transplant allograft rejection. At
the time of this adverse event there had not been any
previously documented cases of allograft rejection with
anti-PD1 agents, and several reports of safe administration
of anti-CTLA-4 [4–6]. We had originally planned for
allograft extraction after the patient’s condition stabilized
on hemodialysis; however, melanoma disease progression
ultimately required more urgent systemic treatment and
we monitored the patient closely after resumption of
nivolumab. The result was an objective response to treat-
ment to nivolumab which is ongoing. The timing of allo-
graft rejection in reference to first-dose administration of
nivolumab implies causality, especially in light of the
chronicity of the allograft (>10 years) and suggests T-cell-
mediated rejection [7].
We decided to stop all immunosuppression except pred-
nisone (10 mg daily) prior to nivolumab administration.
Although a more conservative reduction in immunosup-
pression may have prevented the transplant from failing,
we were concerned of the effect of immunosuppressive
medications on the anti-tumor effect of nivolumab.
Moreover, a longer waiting period prior to nivolumab ad-
ministration may have ruled out rejection due to titration
of immunosuppressive medications, however, the patient’s
aggressive course of disease suggested a faster timeline for
treatment and there was the option for hemodialysis as
rescue. A less aggressive reduction in immunosuppression
would be warranted with other transplants (e.g. heart, liver
etc.) since transplant failure would inevitably lead to
patient death. The product monograph for nivolumab does
not suggest an adjustment of nivolumab on hemodialysis
[12–14], and in our patient this was safely and effectively
administered while on hemodialysis.
This case study and similar reports [7–10] demon-
strate the importance of post-marketing studies in popu-
lations excluded by pivotal and early-phase clinical trials;
in this case, solid organ transplant recipients (SOTRs).
Potential challenges and risks of immune-checkpoint
inhibition for SOTRs include 1) strong potential for
organ transplant rejection, at least with anti-PD-1/PD-L1
treatment as this case has demonstrated [4]; 2) potential
for reduced anti-tumor activity of immune checkpoint
inhibition, especially after titration of potent immunosup-
pressive medications that can reduce T-cell function; 3)
complicated medical management of addressing organ
failure (e.g. hemodialysis) and co-morbidities that led to
organ failure (e.g. diabetes); 4) evolving treatment land-
scape with multiple immune checkpoints that differ in
mechanism and tolerability (i.e. CTLA-4 versus PD-1)
[7, 10, 15]. This case also raises the question of whether
patients should be considered for the rather radical
approach of allograft removal in order to become eli-
gible for treatment with anti-PD-1 agents. Although
phase III clinical studies have demonstrated that anti-
PD-1 agents such as nivolumab and pembrolizumab
Fig. 1 Radiographic response to nivolumab on hemodialysis; CT chest exams performed at baseline and 12 weeks after re-initiation of therapy
demonstrates resolution of lung nodules (indicated by the yellow arrows). The hilar lymph node indicated by the red arrow is stable
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have superior efficacy over ipilimumab in metastatic
melanoma [16], individual case reports suggest that
anti-CTLA-4 agents may be preferred for use in SOTRs
due to the non-peripheral tissue-specific mechanism of
the CTLA-4 receptor compared to PD-1, which would
be less likely to be associated with acute rejection of
the allograft.
It is also important to note that allograft rejection
occurred with both nivolumab and pembrolizumab [7]
which is expected as the two anti-PD-1 antibodies
possess similar therapeutic mechanisms. We suggest that
the characterization of PD-L1 expression on renal allo-
grafts prior to administering an anti-PD-1 agent may
allow the stratification of patients at high risk of rejec-
tion upon treatment. To date, no studies have character-
ized PD-L1 expression on a series of renal transplants
correlating expression levels with rejection following
anti-PD-1 therapy. It has however been demonstrated
that PD-1 expressing T-cell subsets are indicators of risk
of rejection of renal transplants [17].
Approximately half of all SOTRs will develop a skin
malignancy, with squamous cell and basal cell carcinomas
accounting for 90 % [18]. SOTRs have a 2.4 increased risk
of developing melanoma [19], and a retrospective review
by Brewer et al. demonstrated that SOTRs with thick
melanomas (Clark level III or IV or a Breslow thickness of
1.5-3.0 mm) had a significantly poorer melanoma cause-
specific survival rate [20]. The introduction of effective
therapies such as nivolumab in patients with prior solid
organ transplants will have to take into consideration the
risk of promoting foreign antibody from the graft leading
to rejection, versus the benefit of treating their melanoma,
especially when the prognosis is compromised. We
suggest that treating SOTRs with immune checkpoint
blockade could be more dangerous in non-renal trans-
plant recipients (e.g. cardiac, pulmonary, and hepatic)
where organ-replacement therapy equivalent to dialysis is
unavailable [21].
The exclusion of immunosuppressed patients or pa-
tients with an existing autoimmune disorder in clinical
trials investigating the safety of anti-PD-1/anti-PD-L1
agents has left us dependent on case report studies
where to our knowledge, no group has been able to treat
a melanoma (or other skin malignancy) with these anti-
bodies without causing acute graft rejection [7–10]. A
retrospective review of patients with advanced melan-
oma and pre-existing autoimmune disorders has only
been conducted for patients who received ipilimumab
(anti-CTLA-4) and results showed generally exacerba-
tions of their autoimmune symptoms that were manage-
able [22]. Nonetheless, from murine transplant models,
we have learned that the PD-1 pathway is critical for the
induction and maintenance of transplantation tolerance
[15]. Furthermore, CTLA-4 and PD-1 agonists are
emerging as immunosuppressive agents for SOTRs [23,
24]. Therefore, graft rejection may have been predictable
in this case.
While patients are now living longer and better with
organ transplants, their immunosuppressive environ-
ment is allowing the development of an increasing bur-
den of transplant-related malignancies. The development
of novel immunosuppressive drugs that reduce risk of
malignancy, as well as surveillance and monitoring strat-
egies should be considered for the management of can-
cer in SOTRs. One emerging and promising area is the
use of mTOR inhibitors for immunosuppression com-
pared to calcineurin inhibitor-based regimens which
have shown to decrease risk of malignancy [25]. Further
studies to prevent and manage malignancies in this
complicated situation are required.
Abbrevations
CTLA-4: Anti-cytotoxic T-lymphocyte-associated protein-4;
FDG: Fluorodeoxyglucose; GFR: Glomerular filtration rate; IgG-
4: Immunoglobulin G-4; irRC: Immune-related response criteria;
IV: Intravenous; PCR: Polymerase chain reaction; PD-1: Programmed death
receptor-1; PD-L1: Programmed death receptor-1 ligand; PET-CT: Positron
emission tomography-computed tomography; RLL: Right lower lobe;
SOTR: Solid organ transplant recipient; SUV: Standardized uptake value
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